NextCell publishes its Interim Report 2 2023/2024

April 25, 2024

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2023 – Februari 29, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Second quarter (2023-12-01 until 2024-02-29)

● Operating Income amounted to 2,405 (2,734) TSEK, of which
Cellaviva amounted to 2,334 (2,107) TSEK.
● Net Income amounted to 2,334 (2,106) TSEK.
● Operating result amounted to -10,093 (-11,408) TSEK.
● Earnings per share* amounted to -0.29 (-0.33) SEK.
● Cash and bank amounted to 30,393 (77,617) TSEK.
● Solidity amounted to 79.2 (89,3)

First half year (2023-09-01 until 2024-02-29)**

● Operating Income amounted to 7,099 (5,746) TSEK, of which
Cellaviva amounted to 6,580 (4,244) TSEK.
● Net Income amounted to 6,580 (4,244) TSEK.
● Operating result amounted to -19,889 (-20,327) TSEK.
● Earnings per share* amounted to -0.58 (-0.59) SEK.

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2023/2024: 34,379,523 (34,379,523) shares. Number of shares in NextCell as of February 29, 2024: 34,379,523 (34,379,523) shares.
**Solidity: Equity to total balance sheet.

Significant events in the second quarter

● At the end of January, NextCell published an update on the ongoing clinical trials. The largest ongoing study – ProTrans Young, which includes 66 patients – is progressing well.

● At the end of February, NextCell Pharma announced that it had decided on a new strategic direction. The strategic changes means that Cellaviva will become a wholly owned subsidiary and also cost savings as a result of staff reductions.

Significant events after the reporting period

● NextCell announced in early March that it was establishing the subsidiary QVance to meet a Nordic demand for quality analyses. The launch is a strategic addition to NextCell to increase the company's sales and presence in the market for advanced therapy drugs.

● At the end of March, the company announced that the Swedish Medical Products Agency had approved the application to conduct a subgroup analysis of the treatment effect of ProTrans in 30 adolescents in the age group 12-21 years treated in the ProTrans-Young study. The approval for the subgroup analysis by the Swedish Medical Products Agency means that the primary efficacy endpoint readout is available after 12 months. Results from the subgroup analysis are planned to be presented in the second quarter of 2025.

● In mid-April, Nextcell Pharma announced that its longtime Chairman of the Board, Anders Essen-Möller, after ten years of dedicated leadership, will step down from his role on May 20, 2024 due to health reasons.

● NextCell announced in mid-April that the Health and Social Care Inspectorate (IVO) has granted their tissue facility Cellaviva permission to handle the amniotic tissue.

● On April 24th the company announced that the Board of Directors resolves on a rights issue of units of approximately SEK 40.1 million, subject to approval by an Extraordinary General Meeting.

● On April 24th NextCell gave notice of an Extraordinary General Meeting to be held May 27th.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-04-2024 07:30 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company that is in phase 2 studies with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase 3 study. ProTrans is manufactured utilizing the patented platform technology for selection of optimal cells with potency to treat inflammatory disorders including autoimmune diseases. NextCell owns Cellaviva, the largest stem cell bank in the Nordics and QVance, a quality analysis CRO company in start up.

Download attachment Read full press release on Cision (external link)

2019-06-20

Final patient treated in the phase II part of the ProTrans-1 trial

NextCell Pharma AB (NextCell) today treated the last diabetic patient in the phase II part of the ProTrans-1 trial. This means that all patients included in the clinical study have been treated and are now subject to a 12-month follow-up period before efficacy and safety data will be available. The final patient has been treated in the randomized, placebo controlled ProTrans-1 phase II part trial. Efficacy and safety data will be collected through regular clinical assessments visits during a 12 month period. Last patient, last will be assessed in July 2020 and thereafter the code will be

Read more Read more

2019-06-20

New collaboration and increased digital presence - Cellaviva is gearing for growth

NextCell Pharma AB ("NextCell") today announces that they, via its biobank Cellaviva, have entered into a partnership with Bonzun Health Information AB ("Bonzun"), who are providing the first global health app for pregnant women. Bonzun has launched the first virtual midwife for pregnant women which can be downloaded in Appstores under the name Bonzun Pregnant. The app is currently available in 79 countries worldwide under the name Bonzun and in Sweden under the name Min Graviditet. The collaboration has been entered into with the common goal of strengthening the work of sharing knowledge

Read more Read more

2019-06-19

NextCell has treated the first patient in the ProTrans-Repeat trial

NextCell Pharma AB (NextCell) announces that earlier today the first patient was treated as part of the ProTrans-Repeat trial, which is NextCell’s second clinical trial. ProTrans-Repeat is a Phase IIa clinical trial which includes patients receiving active treatment with ProTrans and who have previously been treated in the ProTrans-1 study's dose escalation phase. This means that the participants receive their second treatment with ProTrans, just over a year after the first. The goal of the ProTrans-Repeat trial is to test whether repeated treatment can increase or maintain the effect of

Read more Read more

2019-06-11

Anders Essen-Möller subscribes to his entire stakes in NextCell Pharmas right issue

The two largest owners of NextCell Pharma AB (“NextCell” or “The Company”) Anders Essen-Möller and Diamyd Medical AB, fully subscribe for their respective shares in NextCells ongoing rights issue. This means that both parties consolidate their ownership interests and that Essen-Möllers ownership in NextCell after the investments increases from approximately SEK 3.6 million to 6.0 million. Regarding the ongoing rights issue in NextCell, the principal owner Anders Essen-Möller, also the chairman of the company, has chosen to fully utilize its allotted subscription rights, which means that he

Read more Read more

2019-06-05

Selected to participate in the EIT Health Start.Smart.Global (SSG) programme.

NextCell Pharma AB (publ) ("NextCell") has been chosen as one of a select group of companies to participate in the EIT Health Start.Smart.Global (SSG) programme. The programme focusses on helping European life science SMEs successful entries into Japan and South Korea. EIT Health is a Knowledge and Innovation Community established by the European Institute for Innovation & Technology (EIT) (https://eit.europa.eu/), an independent EU body set up to promote innovation and entrepreneurship across Europe. The EIT Health Start.Smart.Global (SSG) programme, helps European life science SMEs

Read more Read more

2019-05-17

NextCell now has two parallel running clinical trials, ProTrans-1 and ProTrans-Repeat which was initiated today

NextCell Pharma AB (NextCell) announces that the initiation meeting for ProTrans-Repeat was held today at Karolinska University Hospital in Huddinge. ProTrans-Repeat is a completely independent trial and has no effect on the ProTrans-1 study. NextCell now has two ongoing clinical trials that run parallel and according to plan. ProTrans-Repeat's Principal investigator Professor Per-Ola Carlsson and the study team from Karolinska Trial Alliance, together with NextCell, went through the last practical details, which means that the new study has now been formally initiated. ProTrans-Repeat means

Read more Read more

2019-05-17

Rectification: Six out of nine patients in the first part of the phase I/II trial, ProTrans-1 have completed treatment

NextCell Pharma AB (NextCell) announces that six out of the nine patients included in the dose escalation part of ProTrans-1, the trial with the drug candidate ProTrans, now have completed treatment and left the study. Earlier this week, the last of the three patients in the so-called medium-dose-cohort visited for their 12-month follow-up, the final part of the trial, which means that all three now have completed their part of the trial. In early March, the three patients in the low-dose cohort had already completed the trial. This means that six out of nine patients in the phase I part

Read more Read more

2019-05-17

Six out of nine patients in the phase-II part of the ProTrans-1 study have completed treatment

NextCell Pharma AB (NextCell) announces that six out of the nine patients included in ProTrans-1, the trial with the drug candidate ProTrans, now have completed treatment and left the study. Earlier this week, the last of the three patients in the so-called medium-dose-cohort visited for their 12-month follow-up, the final part of the trial, which means that all three now have completed their part of the trial. In early March, the three patients in the low-dose cohort had already completed the trial. This means that six out of nine patients in the phase II part have now successfully

Read more Read more

NextCell publishes its Interim Report 2 2023/2024

Second quarter (2023-12-01 until 2024-02-29)

● Operating Income amounted to 7,099 (5,746) TSEK, of which Cellaviva amounted to 6,580 (4,244) TSEK. ● Net Income amounted to 6,580 (4,244) TSEK. ● Operating result amounted to -19,889 (-20,327) TSEK. ● Earnings per share* amounted to -0.58 (-0.59) SEK.

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2023/2024: 34,379,523 (34,379,523) shares. Number of shares in NextCell as of February 29, 2024: 34,379,523 (34,379,523) shares. **Solidity: Equity to total balance sheet.

Significant events in the second quarter

Significant events after the reporting period

● Operating Income amounted to 7,099 (5,746) TSEK, of which
Cellaviva amounted to 6,580 (4,244) TSEK.
● Net Income amounted to 6,580 (4,244) TSEK.
● Operating result amounted to -19,889 (-20,327) TSEK.
● Earnings per share* amounted to -0.58 (-0.59) SEK.

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2023/2024: 34,379,523 (34,379,523) shares. Number of shares in NextCell as of February 29, 2024: 34,379,523 (34,379,523) shares.
**Solidity: Equity to total balance sheet.